Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Breckenridge Pharmaceutical, Inc. |
| NDC | 51991-748-90 |
| Full product label | Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90. |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Distribution | Nationwide in the USA |
| Quantity | 165,761 90-count bottles |
| Recall initiated | 2026-04-21 |
| Report date | 2026-05-13 |
| Recall completed | — |
| Recall number | D-0522-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berkeley Heights NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗